The most recent trading session ended with Medtronic (MDT) standing at $80.57, reflecting a +1.37% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.87% gain on the day. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 1.11%.Coming into today, shares of the medical device company had lost 4.33% in the past month. In that same time, the Medical sector lost 6.67%, while the S&P 500 lost 3.97%.Analysts and investors alike will be keeping a close eye on the p ...

Can this struggling healthcare specialist turn things around?Medtronic (MDT -0.21%) is a leading global medical device company with a massive presence that spans more than 150 countries. Its products assist patients with over 70 different health conditions. Investing in the stock is a potentially great way to gain exposure to the healthcare industry as a whole.Over the past five years, however, its shares have been a lackluster investment, falling by 8%. What should you do with Medtronic stock: buy, sell, o ...

健康生活选择 - 美国成年人更倾向于选择健康短暂的生活而非长寿但伴随健康问题的生活[1] 预防性健康措施 - 美国成年人对于预防性健康措施的采取率较低，仅有39%的人进行定期体检，29%的人与医生讨论长寿问题[2] 医疗技术作用 - 医疗技术在帮助人们延长寿命和提高生活质量方面发挥着越来越重要的作用[3] - 医疗技术可以帮助人们更早地发现和治疗疾病，减轻慢性疾病的负担[4]

Moussa81 Buying quality companies at reasonable prices remains a winning investment strategy in my opinion despite all the noise around high-flying Al names on the market today. What's even better is if those stocks pay you a decent yield for holding onto them, which makes natural price volatility easier to bear. This brings me to Medtronic (NYSE:MDT), which I last covered in August with a 'Buy' rating, noting its undervaluation, strong balance sheet, and positioning for international growth. Since my l ...

Altayb/E+ via Getty ImagesIntroduction Allow me to start this article by showing you a chart I have used quite a few times in the past few months. As we can see below, the market has a quite lofty valuation. The S&P 500 traded at 21x earnings going into this month. That's 1.3x its long-term standard deviation. In fact, it's the third-most expensive market since the early 1990s. Only the Dotcom and post-pandemic periods were more expensive. JPMorganThis does not mean that stocks are due for a massive sel ...

公司表现 - 公司股票在过去一个月中表现不佳，与Zacks S&P 500综合指数相比下跌了2.6%[2] - Zacks Medical - Products行业在同一时期下跌了3%[2] 财务状况 - 公司当前季度预计每股收益为1.45美元，同比下降了7.6%[5] - 公司当前财年的预期每股收益为5.20美元，同比下降了1.7%[6] - 公司下一个财年的预期每股收益为5.46美元，同比增长了5.1%[7] 股票评级 - 公司被评为Zacks Rank 3 (Hold)，表明股票在短期内可能与整体市场表现一致[8] 盈利能力 - 公司在过去四个季度中均超过了一致预期的每股收益[13] 估值 - 公司被评为B级，表明其股票价格相对同行公司存在折价[17]

Medtronic plc (MDT) recently presented positive clinical trial safety and efficacy results for Sphere-360 -- an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy The catheter is intended for treatment of patients with paroxysmal atrial fibrillation (AFib).The European Heart Rhythm Association (EHRA) 2024 Annual Meeting featured a late-breaking clinical trial showcasing interim findings from the first-in-human Sphere-360 investigation.About Sphere-360 CatheterThe Sphere ...

医疗人工智能市场 - 全球医疗人工智能市场价值在2022年达到163亿美元，预计将以40.2%的复合年增长率增长至2029年的1735.5亿美元[1] - AI在医疗影像技术中的应用是健康科技公司的重要趋势[2] Treatment与aiXplain合作 - Treatment AI与aiXplain合作，通过aiXplain的AI市场扩展了对Treatment的全球医学库的访问[2] - Treatment建立了全球最智能、个性化的医疗AI引擎GLM，与aiXplain合作使医疗机构能够通过其开发框架访问GLM[3] - Treatment和aiXplain计划通过合作探索国际机会，共同开发新的商业应用和解决方案[4]

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care. GI Genius™ wa ...

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation SystemDUBLIN and BERLIN, April 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial ...